Polaris Ventures

Visit Our Blog

This content requires the Flash Plugin.

Founded in 1996, Polaris has backed and played a lead role in developing some of the most successful information technology and life sciences companies in the United States and Europe.

Diversification - across and within industries, and in stage - is the cornerstone of Polaris' investment strategy.

We have built an exceptional team of venture capitalists and technology executives with a broad range of investment and operating experience, the highest business standards, and a commitment to success.

Helping build first-rate management teams is a key commitment we make to the companies we back. Our on-staff team has recruited to our portfolio companies more than 50 executives for a wide range of positions without the use of an outside recruiter, from CEO to the director level.

Polaris has backed many companies that have become stars in their fields.

5 Steps to a Successful Sales Partnership

A sales partnership can do wonders for your top line. It can also antagonize your sales team and cause all kinds of infighting. How to get it right.

Full Story

The NFL Draft & the Performance of Athletes� Performance

It�s an exciting time to be an investor in Athletes� Performance (AP), the trailblazing performance training network for both elite athletes and those wanting to achieve peak fitness.

Full Story

How to Hire in a Bad Economy: 5 Tips

You'd think it would be easier to hire in a bad economy, but it's not. Here's why, and what to do about it.

Full Story



4/24/2012 Alimera Sciences (ALIM) Release: ILUVIEN(R) Receives Marketing Authorization in Austria for the Treatment of Chronic Diabetic Macular Edema

4/12/2012 Shire picks up Pervasis in potential $200M deal 4/12/2012 Progress for Pervasis and InVivo: A Boost for Regenerative Efforts? 4/19/12 4/11/2012 3M Acquires CodeRyte - Acquisition of NLP Technology will Advance 3M Documentation and Coding Solutions



4/17/2012 Dogpatch Labs Europe start-up hub sees six US$1m-plus investments

1/26/2012 Celgene Buys Avila for $350M, Gaining Promising �Covalent� Drugs 1/24/2012 This could be the year of nanotech-enabled medicines 1/20/2012 Start-ups saw big rise in funding during �11 - Biotech sector led way in region